Piper Jaffray Has Just Reaffirmed $10.0 Target Price Per Share on Geron (NASDAQ:GERN) stock, While They’ve Also Reiterated Their Overweight Rating


Geron (NASDAQ:GERN) Rating Reaffirmed

In analysts report issued to clients this morning, Piper Jaffray reaffirmed their Overweight rating on Geron (NASDAQ:GERN) shares. The target price provides a possible upside of 97.63% from company’s last price.

Approximately 2.14 million shares of stock traded hands. Geron Corporation (NASDAQ:GERN) has risen 27.78% since May 4, 2015 and is uptrending. It has outperformed by 28.86% the S&P500.

The overall sentiment of institutions has decreased to 1.33 in Q2 2015. Its down 0.02, from 1.35 in 2015Q2. The ratio dived, as 20 institutions have sold all the shares of Geron Corporation that they owned while 25 funds have taken shares off the table. 13 funds have purchased shares for the first time while 47 added to their positions. These institutions now hold 77.58 million shares or 7.91% more than the 71.89 million shares they owned in 2015Q2.

The Fund Opaleye Management Inc. currently is holding shares equating to 2.48% of its total portfolio in Geron Corporation representing a total of 1.83 million shares. Another fund,Nj State Employees Deferred Compensation Plan, is holding a total of 490,000 shares equating to 0.29% of their holdings. Additionally, Carl Domino Inc has a 41,100 share stake in Geron Corporation which represents 0.09% of their total portfolio. The Fund, Tfs Capital Llc, based out of Pennsylvania, has also built up a stake in the stock, which represents a total of 0.09% of their total portfolio. Finally Rotella Capital Management Inc., a fund which is based in the state of Washington reported a total holdings of 56,581 shares.

Geron Corporation is a clinical stage biopharmaceutical firm focused on the development of a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The company has a market cap of $782.92 million. The Firm operates in one segment, the discovery and development of therapeutic products for oncology. It currently has negative earnings. Telomerase is an enzyme that enables cancer cells, including malignant progenitor cells, to maintain telomere length, which provides a capacity for limitless, uncontrolled proliferation.

According to Zacks Investment Research, “Geron Corporation is a scientific research company that is developing techniques for the health services industry. Their research is currently divided in three different areas. First, they are looking into telomeres and telomerase and their roles in cellular aging and cancer. Second, they are looking pluripotent stem cells as a potential source for the manufacturing of replacement cells and tissues. Lastly, the company is researching nuclear transfer as a potential mechanism for generating genetically matched cells and tissues.” Get a free copy of the Zacks research report on Geron Corporation (GERN).